Building off this research, a new study offers further evidence of semaglutide and lowered major cardiac event risk, regardless of how much weight a person loses while taking the GLP-1 medication
Documentation of Harm: Evidence of the financial and personal impact of the injury, including medical bills, pay stubs, and personal journals detailing the daily effects of the condition
View on PubMed Retatrutide: A Triple Incretin Receptor Agonist for Obesity Management Expert review characterising retatrutide as a first-in-class GIP, GLP-1, and glucagon triple receptor agonist, detailing its mechanism of action, pharmacokinetics, and the clinical significance of adding glucagon receptor agonism to produce superior weight loss to dual agonists (Expert Opin Investig Drugs, 2023)
The Free Assessment Quiz The first step is a comprehensive online assessment
Orforglipron has no cardiovascular outcomes data
It is still too early to assess the promise of these cell therapy assets relative to semaglutide and tirzepatide
